Trubion | Wikipedia audio article
Channel: wikipedia tts
Date: 14/01/2019

This is an audio version of the Wikipedia Article:
https://en.wikipedia.org/wiki/Trubion


00:01:10 Former product pipeline
00:01:20 Former technology



Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
https://assistant.google.com/services/invoke/uid/0000001a130b3f91
Other Wikipedia audio articles at:
https://www.youtube.com/results?search_query=wikipedia+tts
Upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts
Speaking Rate: 0.8385078172388981
Voice name: en-GB-Wavenet-D


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
Trubion was a publicly held biopharmaceutical company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. Trubion was acquired by Emergent BioSolutions on October 28, 2010. Trubion was established in 1999 in the State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.
In December 2005, Trubion entered into a collaborative agreement with Wyeth for the development and worldwide commercialization of CD20-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion’s contract with Wyeth extended through December 22, 2009.